Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years

Intensive Hospital-based Adverse Drug Reaction Monitoring Study On Patients Treated By Qingkailing Injection In The Next Two Years

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01764204

Enrollment

30840

Registered

2013-01-09

Start date

2013-01-31

Completion date

2018-01-31

Last updated

2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Drug Events, Adverse Drug Reactions

Brief summary

To highlight the incidence of adverse reactions of Qingkailing Injection.

Interventions

DRUGQingkailing Injection

Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 80 Years

Healthy volunteers

Inclusion criteria

* all the patients treated by Qingkailing Injection in the certain centers(hospitals) in the next 2 years. * in accordance with ethics requirements.

Exclusion criteria

* none.

Design outcomes

Primary

Measure	Time frame
incidence of severe adverse drug reactions	2 years

Secondary

Measure	Time frame
incidence of adverse drug reactions	2 years

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026